ITM-11 significantly improved PFS and OS compared to everolimus in GEP-NET patients, meeting primary and secondary endpoints. Subgroup analyses showed ITM-11's efficacy across tumor grades and prior ...

G enentech, a member of the Roche Group, announced results from two Phase III studies evaluating the efficacy and safety of two doses of investigational vamikibart compared with a ...

Departments of Obstetrics and Gynecology and Medicine, MedStar Georgetown University Hospital and Georgetown University Medical Center, Washington, DC, USA Increased age- and sex-adjusted US fracture ...

The ACHIEVE-5 trial (ClinicalTrials.gov identifier: NCT06109311) was a randomized, double-blind, placebo-controlled study that included 546 T2D patients with inadequate glycemic control on insulin ...

Dosimetry data from a phase 3 (NCT03049189) 1 clinical trial reveals favorable safety and efficacy with 177Lu-edotreotide ...

− Achieved 28% and 33% Reduction in Composite of All-Cause Mortality and Recurrent Cardiovascular Events in the Overall and Monotherapy Populations, Respectively – − Reduced All-Cause Mortality by 36% ...

Proactive strategies, including communication and collaboration, are vital for improving medication adherence in chronic illness. Personalized interventions are crucial for positive health outcomes, ...

Statistically Significant Improvement in Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Versus Placebo at Week 24 (Primary Endpoint) and Week 48 (Secondary Endpoint) ...

Often divided into primary and secondary research, market research helps businesses identify key factors influencing their market, including the competitive landscape, target audience characteristics, ...

Amlitelimab, dosed every four weeks or every 12 weeks, demonstrated statistically significant and clinically meaningful efficacy in skin clearance and disease severity compared to placebo at Week 24, ...